<DOC>
	<DOCNO>NCT00319046</DOCNO>
	<brief_summary>Although miglustat approve treatment mild moderate type 1 Gaucher disease patient unsuitable enzyme replacement therapy ( ERT ) , data require establish long term efficacy , safety tolerability miglustat maintain disease stability switch ERT .</brief_summary>
	<brief_title>Oral Miglustat Adult Patients With Stable Type 1 Gaucher Disease</brief_title>
	<detailed_description />
	<mesh_term>Gaucher Disease</mesh_term>
	<mesh_term>Miglustat</mesh_term>
	<mesh_term>1-Deoxynojirimycin</mesh_term>
	<criteria>1 . Males female age 18 year old 2 . Type 1 Gaucher disease , diagnose glucocerebrosidase assay molecular analysis glucocerebrosidase gene . 3 . Treatment ERT least 3 year , stable dose regimen least last 6 month . 4 . Clinically biologically stable disease previous 2 year , least 2 time point assessment ( include Baseline one potential time point ) , define : Stable organomegaly ( assess magnetic resonance imaging ( MRI ) compute tomography ( CT ) ) : Liver volume within 10 % mean . Spleen volume within 10 % mean . Free progressive symptomatic document bone disease . Hemoglobin level &gt; 11g/dl Mean platelet count &gt; 100x109 /l . Chitotriosidase activity within 20 % mean . If chitotriosidase available ( case chitotriosidase deficiency , determine ) , relevant biomarkers ( e.g. , angiotensin convert enzyme ( ACE ) , tartrate resistant acid phosphatase ( TRAP ) ferritin ) could consider . 5 . Written informed consent . 1 . History evidence oculomotor gaze palsy , ataxia clinical manifestation typically associate neuronopathic type 3 Gaucher disease . 2 . Not ambulant patient , progressive symptomatic document bone disease . 3 . Splenectomy 18 year age splenomegaly and/or thrombocytopenia . 4 . Peripheral polyneuropathy ( mononeuropathy ) document clinical sign symptom , electrodiagnostic ( EDX ) . 5 . Patients ( male female ) agree use reliable contraception throughout study 3 month cessation miglustat treatment . 6 . Female patient pregnant breast feeding , without pregnancy test prior Day 1 . 7 . History significant lactose intolerance . 8 . Clinically significant diarrhea ( &gt; 3 liquid stool per day &gt; 7 day ) without definable cause within 6 month prior Day 1 , history clinically relevant gastrointestinal disorder . 9 . History cataract know increased risk cataract formation . 10 . Severe renal impairment i.e. , creatinine clearance &lt; 30 ml/min/1.73m^2 11 . Concomitant active medical condition human immunodeficiency virus ( HIV ) hepatitis B/C would render patient unsuitable study . 12 . Previous treatment miglustat .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Type 1 Gaucher Disease</keyword>
	<keyword>miglustat</keyword>
	<keyword>enzyme replacement therapy</keyword>
</DOC>